

[Drug Injury Watch: Disturbing Information About NuvaRing Safety Found In Motions On Experts Recently Unsealed By Federal Court MDL Judge](#)

Newly Available Expert Analysis Of Confidential Drug Company Data Reveals That NuvaRing Estrogen Levels In Studies Were A Cause For Concern, And The Method Of Reporting Was Misleading

(Posted by Tom Lamb at www.DrugInjuryWatch.com on October 3, 2012)

SUMMARY: In early September 2012 Judge Rodney Sippel issued an Order in the federal court NuvaRing MDL litigation that made public for the first time some significant findings in Organon records made by experts retained by Plaintiffs. This expert review information was unavailable until now due to confidentiality claims asserted by the Defendants. Those defense claims were denied by this Order about certain motions related to expert reports.

[\[Read this article in full at original source\]](#)

Earlier NuvaRing articles by Tom Lamb on the Drug Injury Watch blog:

[New 2012 Medical Study Shows NuvaRing Doubles The Risk Of Stroke And Heart Attack, And The Degree Of Risk Increases With Age](#)

[Merck's NuvaRing Increases The Relative Risk For Blood-Clot Side Effects Says Medical Expert After Weighing Competing Studies](#)

[Merck Funded Study Says There Is No Blood Clot Risk With NuvaRing, While BMJ Medical Journal Article Reports A 90% Increased Risk](#)

[950 NuvaRing Lawsuits Pending As Of December 31, 2011 According To Merck Annual Report](#)

[Current First NuvaRing Trial Date: New Jersey State Court Bellwether Case Set For Early February 2013](#)

Attorney [Tom Lamb](#) represents people in personal injury and wrongful death cases involving unsafe prescription drugs or medication errors. The above article was posted originally on his blog, **Drug Injury Watch** – with live links and readers' Comments.
<http://www.DrugInjuryWatch.com>